UCL HUNTINGTON’S DISEASE RESEARCH
A8241021 – The Amaryllis Study
At a glance
About the study
This is a research study of an investigational drug. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
The purpose of this research study is to compare the safety, tolerability and effectiveness of two doses of the investigational drug to placebo on improving voluntary movement and overall symptoms in individuals with Huntington’s disease. A placebo looks like the study medicine but does not contain any active medicine. Researchers use a placebo to see if the study medicine works better or is safer than not taking anything.
What is involved?
The study will last 31 weeks and involves at least 10 study visits to the Leonard Wolfson Experimental Neurology Centre. Visits range between 4 to 7 hours.
During visits there will be questionnaires and other assessments that will provide information to the research staff to assess Huntington’s disease and related symptoms, a person’s ability to perform daily tasks, overall well-being, quality of life and suicidal thoughts or behaviours. There will be a blood test at each visit and also on some visits blood pressure tests and an electrocardiogram (ECG – a test that measures and records the electrical activity of the heart).
Who can take part?
- Individuals diagnosed with Huntington’s Disease
- Individuals between 30 and 65 years old (inclusive)
- Individuals who are willing and able to comply with scheduled visits, treatment plans and other study procedures
- Individuals who are not participating in another clinical drug trial
Contact the HD research team on 0203 108 7483 for more information.